316 related articles for article (PubMed ID: 11259625)
21. Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.
Ford J; Boffito M; Maitland D; Hill A; Back D; Khoo S; Nelson M; Moyle G; Gazzard B; Pozniak A
J Antimicrob Chemother; 2006 Nov; 58(5):1009-16. PubMed ID: 16984898
[TBL] [Abstract][Full Text] [Related]
22. Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors.
Washington CB; Flexner C; Sheiner LB; Rosenkranz SL; Segal Y; Aberg JA; Blaschke TF;
Clin Pharmacol Ther; 2003 May; 73(5):406-16. PubMed ID: 12732841
[TBL] [Abstract][Full Text] [Related]
23. HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2).
Gupta A; Zhang Y; Unadkat JD; Mao Q
J Pharmacol Exp Ther; 2004 Jul; 310(1):334-41. PubMed ID: 15007102
[TBL] [Abstract][Full Text] [Related]
24. P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals.
Meaden ER; Hoggard PG; Newton P; Tjia JF; Aldam D; Cornforth D; Lloyd J; Williams I; Back DJ; Khoo SH
J Antimicrob Chemother; 2002 Oct; 50(4):583-8. PubMed ID: 12356805
[TBL] [Abstract][Full Text] [Related]
25. Involvement of P-glycoprotein in the transport of saquinavir and indinavir in rat brain microvessel endothelial and microglia cell lines.
Ronaldson PT; Lee G; Dallas S; Bendayan R
Pharm Res; 2004 May; 21(5):811-8. PubMed ID: 15180339
[TBL] [Abstract][Full Text] [Related]
26. Saquinavir induces stable and functional expression of the multidrug transporter P-glycoprotein in human CD4 T-lymphoblastoid CEMrev cells.
Dupuis ML; Flego M; Molinari A; Cianfriglia M
HIV Med; 2003 Oct; 4(4):338-45. PubMed ID: 14525546
[TBL] [Abstract][Full Text] [Related]
27. Comparative effects on intestinal absorption in situ by P-glycoprotein-modifying HIV protease inhibitors.
Richter M; Gyémánt N; Molnár J; Hilgeroth A
Pharm Res; 2004 Oct; 21(10):1862-6. PubMed ID: 15553233
[TBL] [Abstract][Full Text] [Related]
28. In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity.
Patel J; Buddha B; Dey S; Pal D; Mitra AK
Am J Ther; 2004; 11(4):262-77. PubMed ID: 15266218
[TBL] [Abstract][Full Text] [Related]
29. P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance?
Jones K; Bray PG; Khoo SH; Davey RA; Meaden ER; Ward SA; Back DJ
AIDS; 2001 Jul; 15(11):1353-8. PubMed ID: 11504956
[TBL] [Abstract][Full Text] [Related]
30. Efavirenz does not interact with the ABCB1 transporter at the blood-brain barrier.
Dirson G; Fernandez C; Hindlet P; Roux F; German-Fattal M; Gimenez F; Farinotti R
Pharm Res; 2006 Jul; 23(7):1525-32. PubMed ID: 16779703
[TBL] [Abstract][Full Text] [Related]
31. Dose-dependent increase of saquinavir bioavailability by the pharmaceutic aid cremophor EL.
Martin-Facklam M; Burhenne J; Ding R; Fricker R; Mikus G; Walter-Sack I; Haefeli WE
Br J Clin Pharmacol; 2002 Jun; 53(6):576-81. PubMed ID: 12047481
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir.
Hsu A; Granneman GR; Cao G; Carothers L; el-Shourbagy T; Baroldi P; Erdman K; Brown F; Sun E; Leonard JM
Clin Pharmacol Ther; 1998 Apr; 63(4):453-64. PubMed ID: 9585800
[TBL] [Abstract][Full Text] [Related]
33. P-glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines.
Fujimoto H; Higuchi M; Watanabe H; Koh Y; Ghosh AK; Mitsuya H; Tanoue N; Hamada A; Saito H
Biol Pharm Bull; 2009 Sep; 32(9):1588-93. PubMed ID: 19721237
[TBL] [Abstract][Full Text] [Related]
34. Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience.
van Heeswijk RP; Veldkamp A; Mulder JW; Meenhorst PL; Lange JM; Beijnen JH; Hoetelmans RM
Antivir Ther; 2001 Dec; 6(4):201-29. PubMed ID: 11878403
[TBL] [Abstract][Full Text] [Related]
35. A pharmacokinetic model for evaluating the impact of hepatic and intestinal first-pass loss of saquinavir in the rat.
Lledó-García R; Nácher A; Casabó VG; Merino-Sanjuán M
Drug Metab Dispos; 2011 Feb; 39(2):294-301. PubMed ID: 20978105
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetic interaction between darunavir and saquinavir in HIV-negative volunteers.
Sekar VJ; Lefebvre E; Mariën K; De Pauw M; Vangeneugden T; Hoetelmans RM
Ther Drug Monit; 2007 Dec; 29(6):795-801. PubMed ID: 18043478
[TBL] [Abstract][Full Text] [Related]
37. P-glycoprotein expression in HTLV-III cells after treatment with HIV-1 protease inhibitors.
Sánchez Mdel C; López P; Vélez R; Yamamura Y
Ethn Dis; 2008; 18(2 Suppl 2):S2-60-4. PubMed ID: 18646322
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetic interactions between 20(S)-ginsenoside Rh2 and the HIV protease inhibitor ritonavir in vitro and in vivo.
Shi J; Cao B; Zha WB; Wu XL; Liu LS; Xiao WJ; Gu RR; Sun RB; Yu XY; Zheng T; Li MJ; Wang XW; Zhou J; Mao Y; Ge C; Ma T; Xia WJ; Aa JY; Wang GJ; Liu CX
Acta Pharmacol Sin; 2013 Oct; 34(10):1349-58. PubMed ID: 23892274
[TBL] [Abstract][Full Text] [Related]
39. P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib.
Li W; Sparidans RW; Wang Y; Lebre MC; Wagenaar E; Beijnen JH; Schinkel AH
Int J Cancer; 2018 Oct; 143(8):2029-2038. PubMed ID: 29744867
[TBL] [Abstract][Full Text] [Related]
40. Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood--brain barrier.
van der Sandt IC; Vos CM; Nabulsi L; Blom-Roosemalen MC; Voorwinden HH; de Boer AG; Breimer DD
AIDS; 2001 Mar; 15(4):483-91. PubMed ID: 11242145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
